What we tested, and what actually worked
Every valuation measure we could test, inside every kind of business, over 213282 PIT company-quarters 2006-2026, delisted included. A measure only counts when the cheapest fifth of companies beat the dearest by a margin that held in every period we tested and that survives resampling. Most do not. The failures are listed below the successes, deliberately: a list of only the winners would tell you nothing about how hard they were to find.
Study AV-01 · generated 2026-09-20 · benchmark: S&P 500 total return over the same window · 206 combinations tested, 2 beat the index, 48 were real but still lost to it.
What actually beat the market
The hardest bar, and the only one that would justify buying something: the cheap group had to beat the S&P 500, not merely fall less than the expensive group.
| Business type | Measure | Horizon | Cheapest fifth | Gap to dearest | Sample | Evidence |
|---|---|---|---|---|---|---|
| Pipeline / MLP | Operating cash flow yield | 36m | +4.1 pts | +25.4 pts | 793 | robust |
| Pipeline / MLP | Operating cash flow yield | 24m | +1.4 pts | +18.3 pts | 920 | robust |
Real, but not a reason to buy: "lost less"
These 48 findings passed every statistical test — the gap between cheap and expensive is real and held across periods. But both groups lost to the index; the cheap ones simply lost less. Among small and unprofitable companies that is what "value" mostly means, and it is not a case for owning them. We list them because the gap is genuine and because leaving them out would make the section above look easier to find than it was.
| Business type | Measure | Horizon | Cheapest fifth | Dearest fifth | Beat the index | Sample |
|---|---|---|---|---|---|---|
| Pre-profit medical devices | Earnings yield (EBIT / EV) | 36m | -34.2 pts | -113.8 pts | 31% | 1,181 |
| Pre-profit medical devices | Earnings yield (EBIT / EV) | 24m | -18.5 pts | -82.1 pts | 37% | 1,386 |
| Pre-profit medical devices | Operating cash flow yield | 24m | -40.9 pts | -95.4 pts | 28% | 2,559 |
| Pre-profit medical devices | Operating cash flow yield | 36m | -71.1 pts | -123.3 pts | 20% | 2,081 |
| Pre-profit medical devices | Operating cash flow yield | 12m | -18.6 pts | -61.6 pts | 37% | 3,064 |
| Clinical-stage biotech | Earnings yield (EBIT / EV) | 36m | -76.4 pts | -118.4 pts | 23% | 1,736 |
| Pre-profit medical devices | Earnings yield (EBIT / EV) | 12m | -8.8 pts | -50.5 pts | 39% | 1,576 |
| Clinical-stage biotech | Earnings yield (EBIT / EV) | 24m | -44.2 pts | -78.0 pts | 28% | 2,183 |
| Pre-profit / cash-burning company | Earnings yield (EBIT / EV) | 36m | -23.2 pts | -53.4 pts | 36% | 14,707 |
| Pre-profit medical devices | EV / Sales | 24m | -54.1 pts | -24.4 pts | 25% | 1,232 |
| Profitable medical devices | EV / Sales | 36m | -49.4 pts | -22.5 pts | 24% | 979 |
| Pre-profit / cash-burning company | Earnings yield (EBIT / EV) | 24m | -14.3 pts | -38.1 pts | 39% | 16,353 |
| Clinical-stage biotech | Earnings yield (EBIT / EV) | 12m | -22.4 pts | -43.8 pts | 32% | 2,665 |
| Regulated utility | Operating cash flow yield | 36m | -13.1 pts | -34.5 pts | 36% | 2,832 |
| Profitable medical devices | Operating cash flow yield | 36m | -16.7 pts | -36.3 pts | 41% | 2,138 |
| Clinical-stage biotech | Operating cash flow yield | 24m | -57.1 pts | -76.3 pts | 25% | 10,145 |
| Clinical-stage biotech | Operating cash flow yield | 36m | -91.2 pts | -109.3 pts | 18% | 8,079 |
| Insurance underwriter | Operating cash flow yield | 24m | -0.7 pts | -18.4 pts | 49% | 3,206 |
| Pre-profit / cash-burning company | Earnings yield (EBIT / EV) | 12m | -6.0 pts | -23.2 pts | 44% | 18,227 |
| Insurance underwriter | Operating cash flow yield | 36m | -4.5 pts | -21.6 pts | 48% | 2,811 |
| Clinical-stage biotech | Operating cash flow yield | 12m | -27.6 pts | -43.9 pts | 31% | 12,399 |
| Regulated utility | Operating cash flow yield | 24m | -5.7 pts | -21.8 pts | 42% | 3,159 |
| Profitable medical devices | Earnings yield (EBIT / EV) | 36m | -13.9 pts | -29.4 pts | 40% | 1,097 |
| Profitable medical devices | Earnings yield (EBIT / EV) | 24m | -5.6 pts | -20.3 pts | 46% | 1,267 |
| Pre-profit / cash-burning company | Operating cash flow yield | 12m | -14.1 pts | -28.4 pts | 37% | 21,978 |
| Regulated utility | Earnings yield (EBIT / EV) | 36m | -12.2 pts | -26.3 pts | 34% | 2,806 |
| Pre-profit / cash-burning company | Operating cash flow yield | 24m | -30.5 pts | -43.8 pts | 31% | 18,667 |
| Insurance underwriter | Operating cash flow yield | 12m | -1.3 pts | -13.1 pts | 49% | 3,626 |
| Regulated utility | Earnings yield (EBIT / EV) | 24m | -4.6 pts | -16.3 pts | 42% | 3,113 |
| Pipeline / MLP | EV / EBIT | 36m | -5.0 pts | -16.4 pts | 46% | 700 |
| Profitable medical devices | Operating cash flow yield | 24m | -10.6 pts | -21.1 pts | 42% | 2,436 |
| Profitable medical devices | Earnings yield (EBIT / EV) | 12m | -2.4 pts | -11.3 pts | 47% | 1,460 |
| Regulated utility | Operating cash flow yield | 12m | -2.2 pts | -10.6 pts | 45% | 3,500 |
| Cyclical semiconductor / hardware | EV / Sales | 24m | -6.6 pts | +1.5 pts | 44% | 1,748 |
| Stable cash-generating business | Earnings yield (EBIT / EV) | 24m | -14.1 pts | -20.9 pts | 40% | 30,925 |
| Pipeline / MLP | Price / Earnings | 12m | -10.6 pts | -3.8 pts | 31% | 503 |
| Stable cash-generating business | Earnings yield (EBIT / EV) | 36m | -23.4 pts | -29.8 pts | 37% | 26,930 |
| Commodity producer | Price / Book | 12m | -18.7 pts | -24.1 pts | 37% | 6,884 |
| Pre-profit medical devices | Price / Earnings | 12m | -12.0 pts | -6.6 pts | 39% | 487 |
| Commodity producer | Price / Book | 24m | -40.8 pts | -46.0 pts | 33% | 6,066 |
| Bank | Operating cash flow yield | 12m | -0.8 pts | -5.5 pts | 49% | 11,762 |
| Stable cash-generating business | EV / Sales | 36m | -24.2 pts | -19.7 pts | 38% | 23,386 |
| Stable cash-generating business | Price / Book | 12m | -10.4 pts | -6.0 pts | 39% | 47,468 |
| Stable cash-generating business | Earnings yield (EBIT / EV) | 12m | -5.7 pts | -9.6 pts | 44% | 35,237 |
| Insurance underwriter | Price / Earnings | 12m | -1.2 pts | -4.8 pts | 49% | 2,674 |
| Commodity producer | Price / Book | 36m | -58.4 pts | -61.8 pts | 28% | 5,305 |
| Stable cash-generating business | Price / Earnings | 24m | -12.7 pts | -16.1 pts | 40% | 30,538 |
| Bank | Price / Book | 12m | -0.8 pts | -2.4 pts | 49% | 11,296 |
What did not work at all
These were tested on exactly the same data and are shown so you can see the denominator. A measure fails either because it worked in one period and reversed in another, or because the result cannot be separated from chance.
| Business type | Measure | Horizon | Gap | Sample | Why it failed |
|---|---|---|---|---|---|
| Bank | EV / EBIT | 12m | +1.4 pts | 2,477 | Cannot be told apart from chance. |
| Bank | EV / EBIT | 24m | +5.5 pts | 2,092 | Cannot be told apart from chance. |
| Bank | EV / EBIT | 36m | +8.1 pts | 1,711 | Cannot be told apart from chance. |
| Bank | EV / Sales | 12m | +1.5 pts | 1,371 | Cannot be told apart from chance. |
| Bank | EV / Sales | 24m | +1.3 pts | 1,161 | Cannot be told apart from chance. |
| Bank | EV / Sales | 36m | +6.2 pts | 971 | Cannot be told apart from chance. |
| Bank | Operating cash flow yield | 24m | +3.8 pts | 10,207 | Worked in one period and reversed in another — not usable. |
| Bank | Operating cash flow yield | 36m | +6.5 pts | 8,788 | Worked in one period and reversed in another — not usable. |
| Bank | Earnings yield (EBIT / EV) | 12m | +0.1 pts | 2,645 | Cannot be told apart from chance. |
| Bank | Earnings yield (EBIT / EV) | 24m | +4.3 pts | 2,185 | Cannot be told apart from chance. |
| Bank | Earnings yield (EBIT / EV) | 36m | +7.3 pts | 1,773 | Cannot be told apart from chance. |
| Bank | Price / Book | 24m | +4.8 pts | 10,016 | Worked in one period and reversed in another — not usable. |
| Bank | Price / Book | 36m | +7.0 pts | 8,872 | Worked in one period and reversed in another — not usable. |
| Bank | Price / Earnings | 12m | +4.2 pts | 2,983 | Cannot be told apart from chance. |
| Bank | Price / Earnings | 24m | +5.6 pts | 2,590 | Cannot be told apart from chance. |
| Bank | Price / Earnings | 36m | +10.2 pts | 2,237 | Cannot be told apart from chance. |
| Clinical-stage biotech | EV / Sales | 12m | -5.1 pts | 1,668 | Cannot be told apart from chance. |
| Clinical-stage biotech | EV / Sales | 24m | +0.3 pts | 1,372 | Cannot be told apart from chance. |
| Clinical-stage biotech | EV / Sales | 36m | -16.7 pts | 1,101 | Cannot be told apart from chance. |
| Clinical-stage biotech | Price / Book | 12m | -7.9 pts | 8,761 | Cannot be told apart from chance. |
| Clinical-stage biotech | Price / Book | 24m | -2.5 pts | 7,154 | Cannot be told apart from chance. |
| Clinical-stage biotech | Price / Book | 36m | -6.7 pts | 5,799 | Cannot be told apart from chance. |
| Commodity producer | EV / EBIT | 12m | -3.6 pts | 3,352 | Cannot be told apart from chance. |
| Commodity producer | EV / EBIT | 24m | +4.0 pts | 2,921 | Cannot be told apart from chance. |
| Commodity producer | EV / EBIT | 36m | -4.0 pts | 2,510 | Cannot be told apart from chance. |
| Commodity producer | EV / Sales | 12m | +4.1 pts | 4,224 | Cannot be told apart from chance. |
| Commodity producer | EV / Sales | 24m | +8.3 pts | 3,689 | Cannot be told apart from chance. |
| Commodity producer | EV / Sales | 36m | +16.3 pts | 3,177 | Cannot be told apart from chance. |
| Commodity producer | Operating cash flow yield | 12m | +8.5 pts | 7,048 | Worked in one period and reversed in another — not usable. |
| Commodity producer | Operating cash flow yield | 24m | +8.7 pts | 6,135 | Worked in one period and reversed in another — not usable. |
| Commodity producer | Operating cash flow yield | 36m | +6.2 pts | 5,312 | Worked in one period and reversed in another — not usable. |
| Commodity producer | Earnings yield (EBIT / EV) | 12m | +11.8 pts | 5,413 | Cannot be told apart from chance. |
| Commodity producer | Earnings yield (EBIT / EV) | 24m | +22.0 pts | 4,711 | Cannot be told apart from chance. |
| Commodity producer | Earnings yield (EBIT / EV) | 36m | +21.0 pts | 4,043 | Cannot be told apart from chance. |
| Commodity producer | Price / Earnings | 12m | -3.6 pts | 3,057 | Cannot be told apart from chance. |
| Commodity producer | Price / Earnings | 24m | -6.4 pts | 2,688 | Cannot be told apart from chance. |
| Commodity producer | Price / Earnings | 36m | -8.8 pts | 2,285 | Cannot be told apart from chance. |
| Cyclical semiconductor / hardware | EV / EBIT | 12m | -2.6 pts | 1,782 | Cannot be told apart from chance. |
| Cyclical semiconductor / hardware | EV / EBIT | 24m | -3.1 pts | 1,586 | Cannot be told apart from chance. |
| Cyclical semiconductor / hardware | EV / EBIT | 36m | -5.5 pts | 1,391 | Worked in one period and reversed in another — not usable. |
| Cyclical semiconductor / hardware | EV / Sales | 12m | -3.9 pts | 1,991 | Worked in one period and reversed in another — not usable. |
| Cyclical semiconductor / hardware | EV / Sales | 36m | -0.4 pts | 1,519 | Cannot be told apart from chance. |
| Cyclical semiconductor / hardware | Operating cash flow yield | 12m | -1.1 pts | 3,996 | Cannot be told apart from chance. |
| Cyclical semiconductor / hardware | Operating cash flow yield | 24m | +3.1 pts | 3,512 | Cannot be told apart from chance. |
| Cyclical semiconductor / hardware | Operating cash flow yield | 36m | +11.3 pts | 3,076 | Cannot be told apart from chance. |
| Cyclical semiconductor / hardware | Earnings yield (EBIT / EV) | 12m | -0.8 pts | 2,251 | Cannot be told apart from chance. |
| Cyclical semiconductor / hardware | Earnings yield (EBIT / EV) | 24m | +4.6 pts | 1,983 | Cannot be told apart from chance. |
| Cyclical semiconductor / hardware | Earnings yield (EBIT / EV) | 36m | +5.3 pts | 1,728 | Cannot be told apart from chance. |
| Cyclical semiconductor / hardware | Price / Book | 12m | -0.1 pts | 3,305 | Cannot be told apart from chance. |
| Cyclical semiconductor / hardware | Price / Book | 24m | -1.8 pts | 2,910 | Cannot be told apart from chance. |
| Cyclical semiconductor / hardware | Price / Book | 36m | +2.1 pts | 2,561 | Cannot be told apart from chance. |
| Cyclical semiconductor / hardware | Price / Earnings | 12m | -1.4 pts | 2,565 | Cannot be told apart from chance. |
| Cyclical semiconductor / hardware | Price / Earnings | 24m | -0.1 pts | 2,301 | Cannot be told apart from chance. |
| Cyclical semiconductor / hardware | Price / Earnings | 36m | -2.2 pts | 2,061 | Cannot be told apart from chance. |
| Insurance underwriter | EV / EBIT | 12m | -0.7 pts | 852 | Cannot be told apart from chance. |
| Insurance underwriter | EV / EBIT | 24m | +0.1 pts | 711 | Cannot be told apart from chance. |
| Insurance underwriter | EV / EBIT | 36m | -10.7 pts | 592 | Cannot be told apart from chance. |
| Insurance underwriter | EV / Sales | 12m | -4.0 pts | 1,453 | Cannot be told apart from chance. |
| Insurance underwriter | EV / Sales | 24m | +11.6 pts | 1,252 | Worked in one period and reversed in another — not usable. |
| Insurance underwriter | EV / Sales | 36m | +22.0 pts | 1,083 | Worked in one period and reversed in another — not usable. |
| Insurance underwriter | Earnings yield (EBIT / EV) | 12m | +2.7 pts | 1,091 | Cannot be told apart from chance. |
| Insurance underwriter | Earnings yield (EBIT / EV) | 24m | +0.6 pts | 910 | Cannot be told apart from chance. |
| Insurance underwriter | Earnings yield (EBIT / EV) | 36m | -9.3 pts | 766 | Worked in one period and reversed in another — not usable. |
| Insurance underwriter | Price / Book | 12m | -4.3 pts | 3,534 | Cannot be told apart from chance. |
| Insurance underwriter | Price / Book | 24m | -3.9 pts | 3,175 | Cannot be told apart from chance. |
| Insurance underwriter | Price / Book | 36m | -9.0 pts | 2,846 | Cannot be told apart from chance. |
| Insurance underwriter | Price / Earnings | 24m | +5.2 pts | 2,404 | Cannot be told apart from chance. |
| Insurance underwriter | Price / Earnings | 36m | +2.9 pts | 2,144 | Cannot be told apart from chance. |
| Pre-profit medical devices | EV / Sales | 12m | -15.7 pts | 1,399 | Cannot be told apart from chance. |
| Pre-profit medical devices | EV / Sales | 36m | -36.5 pts | 1,055 | Worked in one period and reversed in another — not usable. |
| Pre-profit medical devices | Price / Book | 12m | -0.8 pts | 3,269 | Cannot be told apart from chance. |
| Pre-profit medical devices | Price / Book | 24m | +0.1 pts | 2,841 | Cannot be told apart from chance. |
| Pre-profit medical devices | Price / Book | 36m | -5.2 pts | 2,433 | Cannot be told apart from chance. |
| Pre-profit medical devices | Price / Earnings | 24m | +8.7 pts | 446 | Cannot be told apart from chance. |
| Pre-profit medical devices | Price / Earnings | 36m | +16.5 pts | 401 | Cannot be told apart from chance. |
| Profitable medical devices | EV / EBIT | 12m | +0.8 pts | 1,152 | Cannot be told apart from chance. |
| Profitable medical devices | EV / EBIT | 24m | +8.1 pts | 1,005 | Worked in one period and reversed in another — not usable. |
| Profitable medical devices | EV / EBIT | 36m | +5.8 pts | 865 | Worked in one period and reversed in another — not usable. |
| Profitable medical devices | EV / Sales | 12m | -5.9 pts | 1,305 | Cannot be told apart from chance. |
| Profitable medical devices | EV / Sales | 24m | -9.9 pts | 1,135 | Cannot be told apart from chance. |
| Profitable medical devices | Operating cash flow yield | 12m | +2.2 pts | 2,767 | Cannot be told apart from chance. |
| Profitable medical devices | Price / Book | 12m | -5.6 pts | 2,240 | Cannot be told apart from chance. |
| Profitable medical devices | Price / Book | 24m | -9.9 pts | 1,990 | Worked in one period and reversed in another — not usable. |
| Profitable medical devices | Price / Book | 36m | -9.1 pts | 1,765 | Cannot be told apart from chance. |
| Profitable medical devices | Price / Earnings | 12m | -3.0 pts | 1,806 | Cannot be told apart from chance. |
| Profitable medical devices | Price / Earnings | 24m | +1.9 pts | 1,611 | Cannot be told apart from chance. |
| Profitable medical devices | Price / Earnings | 36m | +12.9 pts | 1,418 | Cannot be told apart from chance. |
| Pipeline / MLP | EV / EBIT | 12m | +5.8 pts | 901 | Cannot be told apart from chance. |
| Pipeline / MLP | EV / EBIT | 24m | +5.1 pts | 795 | Worked in one period and reversed in another — not usable. |
| Pipeline / MLP | EV / Sales | 12m | -3.5 pts | 654 | Cannot be told apart from chance. |
| Pipeline / MLP | EV / Sales | 24m | -5.1 pts | 570 | Cannot be told apart from chance. |
| Pipeline / MLP | EV / Sales | 36m | +0.9 pts | 484 | Cannot be told apart from chance. |
| Pipeline / MLP | Operating cash flow yield | 12m | +6.7 pts | 1,052 | Worked in one period and reversed in another — not usable. |
| Pipeline / MLP | Earnings yield (EBIT / EV) | 12m | +0.7 pts | 1,079 | Cannot be told apart from chance. |
| Pipeline / MLP | Earnings yield (EBIT / EV) | 24m | +8.8 pts | 954 | Cannot be told apart from chance. |
| Pipeline / MLP | Earnings yield (EBIT / EV) | 36m | +17.1 pts | 844 | Cannot be told apart from chance. |
| Pipeline / MLP | Price / Book | 12m | -4.1 pts | 898 | Cannot be told apart from chance. |
| Pipeline / MLP | Price / Book | 24m | +3.0 pts | 802 | Cannot be told apart from chance. |
| Pipeline / MLP | Price / Book | 36m | +23.1 pts | 700 | Worked in one period and reversed in another — not usable. |
| Pipeline / MLP | Price / Earnings | 24m | -6.5 pts | 441 | Worked in one period and reversed in another — not usable. |
| Pre-profit / cash-burning company | EV / EBIT | 12m | +1.0 pts | 11,178 | Cannot be told apart from chance. |
| Pre-profit / cash-burning company | EV / EBIT | 24m | +1.3 pts | 10,341 | Cannot be told apart from chance. |
| Pre-profit / cash-burning company | EV / EBIT | 36m | +1.1 pts | 9,526 | Cannot be told apart from chance. |
| Pre-profit / cash-burning company | EV / Sales | 12m | -2.7 pts | 14,930 | Cannot be told apart from chance. |
| Pre-profit / cash-burning company | EV / Sales | 24m | -2.2 pts | 13,328 | Cannot be told apart from chance. |
| Pre-profit / cash-burning company | EV / Sales | 36m | 0.0 pts | 11,935 | Cannot be told apart from chance. |
| Pre-profit / cash-burning company | Operating cash flow yield | 36m | +9.8 pts | 15,879 | Cannot be told apart from chance. |
| Pre-profit / cash-burning company | Price / Book | 12m | -2.3 pts | 29,650 | Cannot be told apart from chance. |
| Pre-profit / cash-burning company | Price / Book | 24m | -1.4 pts | 26,544 | Cannot be told apart from chance. |
| Pre-profit / cash-burning company | Price / Book | 36m | -3.5 pts | 23,811 | Cannot be told apart from chance. |
| Pre-profit / cash-burning company | Price / Earnings | 12m | +1.0 pts | 12,200 | Cannot be told apart from chance. |
| Pre-profit / cash-burning company | Price / Earnings | 24m | +1.8 pts | 11,331 | Cannot be told apart from chance. |
| Pre-profit / cash-burning company | Price / Earnings | 36m | +1.8 pts | 10,455 | Cannot be told apart from chance. |
| Equity REIT | EV / EBIT | 12m | -3.2 pts | 1,273 | Cannot be told apart from chance. |
| Equity REIT | EV / EBIT | 24m | -1.2 pts | 1,133 | Cannot be told apart from chance. |
| Equity REIT | EV / EBIT | 36m | -3.2 pts | 996 | Cannot be told apart from chance. |
| Equity REIT | EV / Sales | 12m | -5.4 pts | 1,637 | Cannot be told apart from chance. |
| Equity REIT | EV / Sales | 24m | -12.4 pts | 1,442 | Cannot be told apart from chance. |
| Equity REIT | EV / Sales | 36m | -18.6 pts | 1,268 | Cannot be told apart from chance. |
| Equity REIT | Operating cash flow yield | 12m | +1.3 pts | 7,412 | Cannot be told apart from chance. |
| Equity REIT | Operating cash flow yield | 24m | -0.5 pts | 6,586 | Cannot be told apart from chance. |
| Equity REIT | Operating cash flow yield | 36m | -0.5 pts | 5,802 | Worked in one period and reversed in another — not usable. |
| Equity REIT | Earnings yield (EBIT / EV) | 12m | +1.4 pts | 1,519 | Cannot be told apart from chance. |
| Equity REIT | Earnings yield (EBIT / EV) | 24m | +10.9 pts | 1,337 | Cannot be told apart from chance. |
| Equity REIT | Earnings yield (EBIT / EV) | 36m | +8.0 pts | 1,177 | Cannot be told apart from chance. |
| Equity REIT | Price / Book | 12m | -2.5 pts | 7,669 | Cannot be told apart from chance. |
| Equity REIT | Price / Book | 24m | -2.7 pts | 6,890 | Worked in one period and reversed in another — not usable. |
| Equity REIT | Price / Book | 36m | -7.9 pts | 6,157 | Worked in one period and reversed in another — not usable. |
| Equity REIT | Price / Earnings | 12m | +2.3 pts | 4,100 | Cannot be told apart from chance. |
| Equity REIT | Price / Earnings | 24m | +3.5 pts | 3,680 | Cannot be told apart from chance. |
| Equity REIT | Price / Earnings | 36m | +6.4 pts | 3,258 | Worked in one period and reversed in another — not usable. |
| Stable cash-generating business | EV / EBIT | 12m | -0.2 pts | 28,285 | Cannot be told apart from chance. |
| Stable cash-generating business | EV / EBIT | 24m | -2.4 pts | 24,911 | Cannot be told apart from chance. |
| Stable cash-generating business | EV / EBIT | 36m | -3.9 pts | 21,768 | Cannot be told apart from chance. |
| Stable cash-generating business | EV / Sales | 12m | -1.8 pts | 30,597 | Cannot be told apart from chance. |
| Stable cash-generating business | EV / Sales | 24m | -1.9 pts | 26,870 | Cannot be told apart from chance. |
| Stable cash-generating business | Operating cash flow yield | 12m | +0.4 pts | 56,126 | Cannot be told apart from chance. |
| Stable cash-generating business | Operating cash flow yield | 24m | +1.8 pts | 49,199 | Cannot be told apart from chance. |
| Stable cash-generating business | Operating cash flow yield | 36m | +2.6 pts | 42,740 | Cannot be told apart from chance. |
| Stable cash-generating business | Price / Book | 24m | -4.8 pts | 42,071 | Cannot be told apart from chance. |
| Stable cash-generating business | Price / Book | 36m | -7.1 pts | 37,116 | Cannot be told apart from chance. |
| Stable cash-generating business | Price / Earnings | 12m | +1.9 pts | 34,546 | Cannot be told apart from chance. |
| Stable cash-generating business | Price / Earnings | 36m | +3.8 pts | 26,790 | Cannot be told apart from chance. |
| Regulated utility | EV / EBIT | 12m | +2.2 pts | 2,834 | Cannot be told apart from chance. |
| Regulated utility | EV / EBIT | 24m | +4.9 pts | 2,584 | Cannot be told apart from chance. |
| Regulated utility | EV / EBIT | 36m | +2.0 pts | 2,328 | Cannot be told apart from chance. |
| Regulated utility | EV / Sales | 12m | +0.1 pts | 2,262 | Cannot be told apart from chance. |
| Regulated utility | EV / Sales | 24m | -3.3 pts | 2,062 | Worked in one period and reversed in another — not usable. |
| Regulated utility | EV / Sales | 36m | -11.5 pts | 1,857 | Cannot be told apart from chance. |
| Regulated utility | Earnings yield (EBIT / EV) | 12m | +3.2 pts | 3,420 | Worked in one period and reversed in another — not usable. |
| Regulated utility | Price / Book | 12m | +0.8 pts | 3,551 | Cannot be told apart from chance. |
| Regulated utility | Price / Book | 24m | +1.9 pts | 3,211 | Cannot be told apart from chance. |
| Regulated utility | Price / Book | 36m | +2.7 pts | 2,895 | Cannot be told apart from chance. |
| Regulated utility | Price / Earnings | 12m | +3.4 pts | 1,867 | Cannot be told apart from chance. |
| Regulated utility | Price / Earnings | 24m | +3.7 pts | 1,690 | Cannot be told apart from chance. |
| Regulated utility | Price / Earnings | 36m | +10.5 pts | 1,515 | Cannot be told apart from chance. |
How this was measured
- Every figure is taken as it stood on the day the filing reached the SEC — never a restated number, and never one published after the date it is used on.
- The price history includes companies that were later delisted, carrying whatever actually happened to them. A study run only on today's survivors would flatter every result on this page.
- Companies are ranked against others of the same business type in the same quarter, so a cheap market cannot be mistaken for a cheap company.
- The periods are tested separately. A measure that works in one and reverses in another is marked as such, not averaged into looking useful.
- Confidence comes from resampling whole quarters, which keeps months that moved together from counting as independent evidence.
Testing many combinations at once means a few will look good by luck. That is why agreement across periods is required as well as statistical significance, and why the count of everything tested is printed above rather than only the winners.
